Jan 11 |
Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding
|
Jan 8 |
Atara to conduct $15M registered direct offering
|
Jan 8 |
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
|
Jan 8 |
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
|
Jan 4 |
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
Dec 20 |
Atara Biotherapeutics Announces Closing of Expanded Global Tab-celĀ® Partnership with Pierre Fabre Laboratories
|
Dec 19 |
Atara reportedly laying off 73 workers in wake of failed MS drug study
|
Dec 11 |
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
|
Nov 29 |
Atara Biotherapeutics To Present Positive New Tab-celĀ® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
|
Nov 24 |
Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why
|